Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 301–400 of 1,004
The clinical and biochemical significance of 11-oxygenated androgens in human health and disease
Storbeck, K.-H., & O’Reilly, M. W. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad047 · Cited by 63
Vitamin D, PCOS and androgens in men: a systematic review
Trummer, C., Pilz, S., Schwetz, V., Obermayer-Pietsch, B., & Lerchbaum, E. (2018) · Endocrine Connections · doi:10.1530/ec-18-0009 · Cited by 63
Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 64
Cincione, R. I., Graziadio, C., Marino, F., Vetrani, C., Losavio, F., Savastano, S., Colao, A., & Laudisio, D. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01943-y · Cited by 63
Weng, Y., Zhang, Y., Wang, D., Wang, R., Xiang, Z., Shen, S., Wang, H., Wu, X., Wen, Y., & Wang, Y. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01242-x · Cited by 65
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., et al. (2024) · Medicina · doi:10.3390/medicina60101656 · Cited by 65
“…are currently endorsed However, several names such as “hyperandrogenic–chronic anovulation”, “metabolic reproductive syndrome”, “prevalent cardiometabolic ovary syndrome” or “functional ovarian hyperandrogenism” have been proposed [8–11]. by the majority societies and health organizations [12].”
BackgroundFree androgen index and Irisin in polycystic ovary syndrome
Li, H., Xu, X., Wang, X., Liao, X., Li, L., Yang, G., & Gao, L. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0403-7 · Cited by 63
Carmina, E., Campagna, A. M., Fruzzetti, F., & Løbo, R. A. (2015) · Endocrine Practice · doi:10.4158/ep15903.or · Cited by 63
Inositols in the Treatment of Insulin-Mediated Diseases
Muscogiuri, G., Palomba, S., Laganà, A. S., & Orio, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3058393 · Cited by 56
“Oral contraceptives (OCs) are considered the first-line treatment for menstrual disturbances and hirsutism/acne in patients with PCOS [34, 35], while the use of oral insulinsensitizing compounds such as pioglitazone and metformin is suggested for the treatment of hyperinsulinemic condition of PCOS patients [36].”
BackgroundContemporary approaches to the management of polycystic ovary syndrome
Pasquali, R. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818756790 · Cited by 63
Self-citationLuque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Inflammatory biomarkers and telomere length in women with polycystic ovary syndrome
Pedroso, D. C. C., Furtado, C. L. M., Kogure, G. S., Meola, J., Okuka, M., Silva, C., Calado, R. T., Ferriani, R. A., Keefe, D. L., & dos Reis, R. M. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.10.035 · Cited by 64
de Medeiros, S. F. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-017-0313-y · Cited by 51
Update on childhood/adolescent obesity and its sequela
Kohut, T. J., Robbins, J., & Panganiban, J. A. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000786 · Cited by 63
Butt, M. S., Saleem, J., Aiman, S., Zakar, R., Sadique, I., & Fischer, F. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01782-2 · Cited by 62
“Establishing a diagnosis of PCOS is difficult among adolescents and menopausal women [14].”
BackgroundPoor Sleep Is Related to Metabolic Syndrome Severity in Adolescents With PCOS and Obesity
Simon, S., Rahat, H., Carreau, A.-M., Garcia-Reyes, Y., Halbower, A., Pyle, L., Nadeau, K. J., & Cree-Green, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz285 · Cited by 54
Tsiami, A. P., Goulis, D. G., Sotiriadis, A., & Kolibianakis, E. M. (2021) · HORMONES · doi:10.1007/s42000-021-00289-z · Cited by 60
“1 3 letrozole as first-line treatments [6, 10].”
Li, R., Mai, T., Zheng, S., & Zhang, Y. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06700-3 · Cited by 60
“As we known, metformin is utilized as first-line regimen in PCOS women with metabolic abnormalities in term of insulin resistance, an essential pathophysiology of PCOS [22].”
Shorakae, S., Boyle, J., & Teede, H. (2014) · Internal Medicine Journal · doi:10.1111/imj.12495 · Cited by 49
Vesper, H. W., Wang, Y., Vidal, M., Botelho, J. C., & Caudill, S. P. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.245969 · Cited by 60
“Testosterone measurements are necessary for the diagnosis of classic hypogonadism in men and polycystic ovary syndrome in women (8, 9).”
BackgroundBurcu, M., Zito, J. M., Safer, D. J., Magder, L. S., dosReis, S., Shaya, F. T., & Rosenthal, G. L. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.2896 · Cited by 52
Polycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences
Yau, T., Ng, N. Y. H., Cheung, L., & Ronald, C. W. (2017) · Hong Kong Medical Journal · doi:10.12809/hkmj176308 · Cited by 62
New perspectives on the definition and management of polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0832-1 · Cited by 61
Self-citationJiang, B., Xue, M., Xu, D., Song, J., & Zhu, S. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14753 · Cited by 58
Esmaeilian, Y., Hela, F., Bildik, G., İltumur, E., Yusufoğlu, S., Yildiz, C. S., Yakın, K., Kordan, Y., & Öktem, Ö. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05864-3 · Cited by 58
Polycystic Ovary Syndrome and Insulin: Our Understanding in the Past, Present and Future
Mayer, S., Evans, W. S., & Nestler, J. E. (2015) · Women s Health · doi:10.2217/whe.14.73 · Cited by 61
Lindheim, L., Bashir, M., Münzker, J., Trummer, C., Zachhuber, V., Pieber, T. R., Gorkiewicz, G., & Obermayer-Pietsch, B. M. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01270 · Cited by 58
“Currently, the Endocrine Society recommends the use of the Rotterdam Criteria for the diagnosis of PCOS (Legro et al., 2013).”
MethodPolycystic ovarian syndrome: clinical and biological diagnosis
Bachelot, A. (2016) · Annales de biologie clinique · doi:10.1684/abc.2016.1184 · Cited by 58
Paul, T., Satyaraddi, A., Cherian, K., Kapoor, N., Kunjummen, A., Kamath, M., & Thomas, N. (2019) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_2_19 · Cited by 57
“Women who were 18–35 years of age with phenotypic features of PCOS and fulfilling the Rotterdam criteria[15] for the diagnosis of PCOS were included in the study.”
Garzia, E., Galiano, V., Marfia, G., Navone, S. E., Grossi, E., & Marconi, A. M. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00876-0 · Cited by 57
“While on the one hand a symptomatic approach may be appropriate for some women, in subjects with severe endocrine and metabolic abnormalities, pathogenesis-focused treatment is required to act on the various clinical manifestations and to allow long-lasting effects [11].”
BackgroundResultAşık, M., Altınbaş, K., Eroğlu, M., Karaahmet, E., Erbağ, G., Ertekin, H., & Şen, H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.043 · Cited by 57
“current studies demonstrate an increased prevalence of depressive symptoms and disorders (Legro et al., 2013).”
BackgroundInfluentialPawelczak, M., Rosenthal, J., Milla, S., Liu, Y.-H., & Shah, B. (2014) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2014.01.104 · Cited by 52
“The diagnosis of PCOS was based on the revised 2003 ESHRE/ ASRM Rotterdam criteria, which require 2 of the 3 following characteristics: (1) oligo/anovulation, (2) clinical/biochemical signs of hyperandrogenism, and/or (3) polycystic ovaries on US (the presence of 12 or more follicles measuring 2-9mm in diameter and/or…”
MethodEsmaeilzadeh, S., Andarieh, M. G., Ghadimi, R., & Delavar, M. A. (2014) · Global Journal of Health Science · doi:10.5539/gjhs.v7n2p101 · Cited by 57
Evans, M., Morgan, A. R., Patel, D., Dhatariya, K., Greenwood, S. A., Newland‐Jones, P., Hicks, D., Yousef, Z. R., Moore, J., Kelly, B., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00963-2 · Cited by 58
Hyperinsulinaemic androgen excess in adolescent girls
Ibáñez, L., Ong, K. K., López-Bermejo, A., Dunger, D. B., & de Zegher, F. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.58 · Cited by 56
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
The post-translational regulation of 17,20 lyase activity
Miller, W. L., & Tee, M. K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.010 · Cited by 56
“PCOS is a common hyperandrogenic disorder affecting about 6% of women of reproductive age, principally characterized by hyperandrogenism and associated with insulin resistance and metabolic syndrome (reviewed by Diamanti-Kandarakis and Dunaif, 2012 and by Legro et al., 2013).”
BackgroundMardon, A. K., Leake, H. B., Szeto, K., Astill, T., Hilton, S., Moseley, G. L., & Chalmers, K. J. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17064 · Cited by 56
“Improving the quality of CPGs for the management of PPP T A B L E 3 Summary of intervention recommendations across clinical practice guidelines Chronic pelvic pain Endometriosis Polycystic ovarian syndrome Vulvodynia Interstitial cystitis Dysmenorrhoea Genito- pelvic pain and penetration disorder Intervention recommen…”
BackgroundInfluentialKim, J. Y., Tfayli, H., Michaliszyn, S. F., & Arslanian, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01958 · Cited by 55
Self-citationHughan, K. S., Tfayli, H., Warren-Ulanch, J. G., Barinas-Mitchell, E., & Arslanian, S. A. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.09.082 · Cited by 53
Self-citationWorsley, R., Santoro, N. F., Miller, K. K., Parish, S. J., & Davis, S. R. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2015.12.014 · Cited by 55
Ibáñez, L., del Río, L., Díaz, M., Sebastiani, G., Pozo, Ó. J., López‐Bermejo, A., & de Zegher, F. (2017) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2017.04.010 · Cited by 55
Ferjan, S., Janež, A., & Jensterle, M. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0027 · Cited by 55
McAllister, J. M., Han, A. X., Modi, B. P., Teves, M. E., Mavodza, G. R., Anderson, Z. L., Shen, T., Christenson, L. K., Archer, K. J., & Strauss, J. F. (2019) · Endocrinology · doi:10.1210/en.2019-00013 · Cited by 56
Peng, Y., Yang, X., Luo, X., Liu, C., Cao, X., Wang, H., & Guo, L. (2020) · Biological Research · doi:10.1186/s40659-020-00317-z · Cited by 55
The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome
Bourgneuf, C., Bailbé, D., Lamazière, A., Dupont, C., Moldes, M., Farabos, D., Roblot, N., Gauthier, C., d’Argent, E. M., Cohen-Tannoudji, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21308-y · Cited by 56
Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome
Kim, J. Y., Tfayli, H., Michaliszyn, S. F., Lee, S., Nasr, A., & Arslanian, S. (2017) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2016.10.015 · Cited by 54
“Given the heterogeneous nature of this condition, various combinations of clinical, biological, and ultrasonographic criteria have been proposed for the diagnosis of PCOS in adult women [2,3] and adolescent girls [1,4].”
Self-citationPolycystic ovarian syndrome awareness among females in the UAE: a cross-sectional study
Zaitoun, B., Kubaisi, A. A., AlQattan, N., Alassouli, Y. M., Mohammad, A., Alameeri, H., & Mohammed, G. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02318-y · Cited by 55
Villarroel, C., López, P., Merino, P. M., Iñiguez, G., Sir-Petermann, T., & Codner, E. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1025380 · Cited by 46
Androgen excess in breast cancer development: implications for prevention and treatment
Secreto, G., Girombelli, A., & Krogh, V. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0429 · Cited by 54
Hypertension in Polycystic Ovary Syndrome: Novel Insights
Macut, D., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Milutinović, D. V., & Andrić, Z. (2020) · Current Hypertension Reviews · doi:10.2174/1573402115666190531071422 · Cited by 42
Jensterle, M., Kravos, N. A., Ferjan, S., Goričar, K., Dolžan, V., & Janež, A. (2020) · Endocrine Connections · doi:10.1530/ec-19-0449 · Cited by 54
Vine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
Spironolactone in the treatment of polycystic ovary syndrome
Armanini, D., Andrisani, A., Bordin, L., & Sabbadin, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215430 · Cited by 53
Wright, P. J., Dawson, R. M., & Corbett, C. F. (2020) · Journal of Advanced Nursing · doi:10.1111/jan.14371 · Cited by 53
Pregnancy outcomes in women with polycystic ovarian syndrome
D’Alterio, M. N., Sigilli, M., Succu, A. G., GHISU, V., Laganà, A. S., Sorrentino, F., Nappi, L., Tinelli, R., & Angioni, S. L. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04758-4 · Cited by 54
Exercise Recommendations for Women with Polycystic Ovary Syndrome: Is the Evidence Enough?
Stepto, N. K., Patten, R. K., Tassone, E. C., Misso, M. L., Brennan, L., Boyle, J. A., Boyle, R. A., Harrison, C. L., Hirschberg, A. L., Marsh, K. A., et al. (2019) · Sports Medicine · doi:10.1007/s40279-019-01133-6 · Cited by 55
Jarrett, B. Y., Brink, H. V., Oldfield, A. L., & Lujan, M. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa515 · Cited by 54
Does the Ketogenic Diet Improve the Quality of Ovarian Function in Obese Women?
Magagnini, M. C., Condorelli, R. A., Cimino, L., Cannarella, R., Aversa, A., Calogero, A. E., & La Vignera, S. (2022) · Nutrients · doi:10.3390/nu14194147 · Cited by 52
“In these cases, the measurement of mid-luteal serum progesterone may help as an additional screening test [24].”
BackgroundMethodMetformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Huang, C.-C., Tien, Y.-J., Chen, M.-J., Chen, C.-H., Ho, H.-N., & Yang, Y.-S. (2015) · Human Reproduction · doi:10.1093/humrep/dev010 · Cited by 43
“Some authors emphasized the phenotypes of clinical HA such as hirsutism and alopecia (Legro et al., 2013), while others highlighted the effect of obesity toward metabolic aberrations (Moran and Teede, 2009).”
BackgroundAssociation of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy
Ezewuiro, O., Grushko, T. A., Kocherginsky, M., Habis, M., Hurteau, J. A., Mills, K. A., Hunn, J., Olopade, O. I., Fleming, G. F., & Romero, I. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147145 · Cited by 50
“Metformin was approved by the Food and Drug Administration (FDA) for diabetes treatment in 1995, and was later recommended as first line therapy for type II diabetes by the American Diabetes Association [2].”
BackgroundAre expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?
Copp, T., Jansen, J., Doust, J., Mol, B. W., Dokras, A., & McCaffery, K. (2017) · BMJ · doi:10.1136/bmj.j3694 · Cited by 43
The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS
Pelanis, R., Mellembakken, J. R., Poromaa, I. S., Ravn, P., Morin-Papunen, L. C., Tapanainen, J. S., Piltonen, T., Puurunen, J., Hirschberg, A. L., Fedorcsák, P., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dex294 · Cited by 52
Dhayat, N. A., Marti, N., Kollmann, Z., Troendle, A., Bally, L., Escher, G., Grössl, M., Ackermann, D., Ponte, B., Pruijm, M., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0203903 · Cited by 43
“In line with that, clinical studies unambiguously show an improvement of hyperandrogenism in PCOS women with weight loss [2].”
BackgroundResultInfluentialNon-alcoholic fatty liver disease in polycystic ovary syndrome women
Won, Y. B., Seo, S. K., Yun, B. H., Cho, S., Choi, Y. S., & Lee, B. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-86697-y · Cited by 53
Shah, D., Patil, M., & On behalf of the National PCOS Working Group (2018) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_72_18 · Cited by 51
“The presence of dyslipidemia may not be a contraindication for the use of OCPs.”
BackgroundInfluentialRamezani Tehrani, F., Minooee, S., & Azizi, F. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0094 · Cited by 51
Identification of subjects with polycystic ovary syndrome using electronic health records
Castro, V., Shen, Y., Yu, S., Finan, S., Pau, C. T., Gainer, V., Keefe, C. C., Savova, G., Murphy, S. N., Cai, T., et al. (2015) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-015-0115-z · Cited by 51
“On the other hand, there can be failure to understand that an elevated laboratory testosterone level is not necessary to make a diagnosis [21] and the ICD-9 code may not be used to indicate a diagnosis that is truly PCOS.”
BackgroundSelf-citationSalehi, S., Allahverdy, J., Pourjafar, H., Sarabandi, K., & Jafari, S. M. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10223-5 · Cited by 51
“We know that IR is one of the causes of PCOS [108–111].”
Yuan, J., Li, Z., Yu, Y., Wang, X., & Zhao, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1520695 · Cited by 51
Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome
Çalan, M., Yılmaz, Ö., Küme, T., Kocabaş, G. Ü., Senses, P. Y., Senses, Y. M., Temür, M., & Çalan, Ö. G. (2016) · Endocrine · doi:10.1007/s12020-016-0875-z · Cited by 51
Endocrine Disruptors and Polycystic Ovary Syndrome: Phthalates
Akın, L., Kendırcı, M., Narin, F., Kurtoğlu, S., Hatipoğlu, N., & Elmalı, F. (2020) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2020.2020.0037 · Cited by 51
“However, as the current Endocrine Society guidelines (16,17) recommend the presence of both hyperandrogenism and chronic anovulation for PCOS diagnosis in adolescence, we excluded the patients with phenotypes 3 and 4.”
BackgroundLerchbaum, E., Theiler‐Schwetz, V., Giuliani, A., & Obermayer-Pietsch, B. M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1035 · Cited by 51
A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents
Wong, J. M. W., Gallagher, M., Gooding, H., Feldman, H. A., Gordon, C. M., Ludwig, D. S., & Ebbeling, C. B. (2016) · Pediatric Obesity · doi:10.1111/ijpo.12047 · Cited by 50
“Treatment guidelines specify lifestyle modification, including weight-loss diets, as the first line of therapy for PCOS among overweight and obese girls (11,12).”
Nybacka, Å., Hellström, P. M., & Hirschberg, A. L. (2017) · Clinical Endocrinology · doi:10.1111/cen.13427 · Cited by 50
Simões‐Pereira, J., Nunes, J., Aguiar, A., Sousa, S., Rodrigues, C., Matias, J. S., & Calhaz–Jorge, C. (2018) · Endocrine · doi:10.1007/s12020-018-1555-y · Cited by 50
Kahal, H., Kyrou, I., Uthman, O., Brown, A., Johnson, S., Wall, P., Metcalfe, A., Tahrani, A. A., & Randeva, H. S. (2018) · Sleep · doi:10.1093/sleep/zsy085 · Cited by 49
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Yen and Jaffe's Reproductive Endocrinology · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 36
Yi, D. Y., Kim, S. C., Lee, J. H., Lee, E. H., Kim, J. Y., Kim, Y. J., Kang, K. S., Hong, J., Shim, J. O., Lee, Y. M., et al. (2018) · Korean Journal of Pediatrics · doi:10.3345/kjp.2018.07360 · Cited by 49
Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function
Jorquera, G., Echiburú, B., Crisosto, N., Sotomayor‐Zárate, R., Maliqueo, M. A., & Cruz, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00653 · Cited by 49
Magzoub, R., Kheirelseid, E. A. H., Perks, C. M., & Lewis, S. J. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2022.01.025 · Cited by 50
Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance
Genazzani, A. D., & Genazzani, A. R. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.71 · Cited by 48
Pecchioli, Y., Oyewumi, L., Allen, L. M., & Kives, S. L. (2016) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2016.09.012 · Cited by 48
Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
Ruan, X., Li, M., & Mueck, A. O. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130104922 · Cited by 43
Tang, L., Yuan, L., Yang, G., Wang, F., Fu, M., Chen, M., & Liu, D. (2019) · Clinical Endocrinology · doi:10.1111/cen.14056 · Cited by 45
Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease
Salva-Pastor, N., Chávez-Tapia, N. C., Uribe, M., & Nuño‐Lámbarri, N. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105445 · Cited by 48
Pregravid contraceptive use and fecundability: prospective cohort study
Yland, J. J., Bresnick, K. A., Hatch, E. E., Wesselink, A. K., Mikkelsen, E. M., Rothman, K. J., Sørensen, H. T., Huybrechts, K. F., & Wise, L. A. (2020) · BMJ · doi:10.1136/bmj.m3966 · Cited by 48
Raeisi, T., Rezaie, H., Darand, M., Taheri, A., Garousi, N., Razi, B., Roever, L., Mohseni, R., Mohammed, S. H., & Alizadeh, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246200 · Cited by 48
“However IR is not necessarily needed for the PCOS diagnosis, it occurs in approximately 50–80% of patients with this syndrome [8], and is considered to play a significant role in its etiology [2].”
BackgroundFSRH Guideline (January 2019, amended October 2023) Combined Hormonal Contraception
(2019) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2018-chc · Cited by 49
Performance of mass spectrometry steroid profiling for diagnosis of polycystic ovary syndrome
Handelsman, D. J., Teede, H. J., Desai, R., Norman, R. J., & Moran, L. J. (2017) · Human Reproduction · doi:10.1093/humrep/dew328 · Cited by 47
“This is consistent with contemporary clinical practice guidelines (Teede et al., 2011; Legro et al., 2013; Conway et al., 2014) which recommend such conventional immunoassay-based measurements, despite their suboptimal biochemical accuracy or confirmation of PCOS diagnosis.”
ResultYing, X., Rongjiong, Z., Kahaer, M., Chunhui, J., & Wulasihan, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1088187 · Cited by 47
“Related studies have reported that metformin can be used to reduce the weight and fat distribution in patients; however, some studies have shown that the effect is not significant (Legro et al., 2013).”
BackgroundOff-label drug use in the treatment of polycystic ovary syndrome
Vitek, W., Alur-Gupta, S., & Hoeger, K. M. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.01.019 · Cited by 48
“Endocrine Society guidelines recommends against it use for ovulation induction, although Australian Alliance guidelines suggest possible benefit in women with body mass index (BMI) %30 kg/m(2) or in combination with clomiphene, but recommends clomiphene instead of metformin alone in women with BMI >30 kg/m(2) (15, 16).”
BackgroundSelf-citationCree-Green, M., Newcomer, B. R., Coe, G., Newnes, L., Baumgartner, A., Brown, M. S., Pyle, L., Reusch, J. E., & Nadeau, K. J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00619.2014 · Cited by 44
Ruan, X., Kubba, A., Aguilar, A., & Mueck, A. O. (2017) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2017.1317735 · Cited by 47
“Investigations and tests for confirming a diagnosis of PCOS [1,9,37].”
BackgroundInfluentialZinc status and polycystic ovarian syndrome: A systematic review and meta-analysis
Abedini, M., Ghaedi, E., Hadi, A., Mohammadi, H., & Amani, R. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.01.002 · Cited by 47
Gariani, K., Hugon‐Rodin, J., Philippé, J., Righini, M., & Blondon, M. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.019 · Cited by 47
The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women
Ilagan-Vega, M. K. C., Paz-Pacheco, E. T., Totesora, D., Clemente-Chua, L. R., & Jalique, J. R. K. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.4.374 · Cited by 47
Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity
Hudnut‐Beumler, J., Kaar, J. L., Taylor, A., Kelsey, M. M., Nadeau, K. J., Zeitler, P., Snell‐Bergeon, J., Pyle, L., & Cree‐Green, M. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13206 · Cited by 46
“Whereas the Endocrine Society guidelines recommend an OGTT or an HbA1c for diabetes screening, more recent PCOS guidelines recommend repeated OGTT's in the setting of obesity.(1,13) However, our data indicate that a pre-diabetes HbA1c is predictive of future T2D in this patient cohort, and conversely, a normal HbA1c w…”
BackgroundTabrizi, F. P. F., Farhangi, M. A., Vaezi, M., & Hemmati, S. (2020) · Nutrition Journal · doi:10.1186/s12937-020-00601-4 · Cited by 46
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.